Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Neoplasms 5 Hemorrhage 5 Hematologic Neoplasms 3 Head and Neck Neoplasms 2 Brain Neoplasms 2 Bone Neoplasms 2 Recurrence 1 Prostatic Neoplasms 1 Postoperative Complications 1 Osteosarcoma 1 Myofibroma 1 Metrorrhagia 1 Meningioma 1 Melanoma 1 Leiomyoma 1 Glioma 1 Breast Neoplasms 1 Astrocytoma 1

Interventions

Dacarbazine 25 Nivolumab 24 pembrolizumab 19 Ipilimumab 18 Interferon-alpha 10 trametinib 8 Vemurafenib 8 dabrafenib 7 aldesleukin 7 Temozolomide 7 Introns 7 Interferon alpha-2 6 Interleukin-2 5 Cisplatin 5 Chemotherapy, Adjuvant 5 talimogene laherparepvec 4 cemiplimab 4 binimetinib 4 Radiotherapy 4 Paclitaxel 4 Granulocyte-Macrophage Colony-Stimulating Factor 4 sargramostim 3 encorafenib 3 cobimetinib 3 Vinblastine 3 Surgical Procedures, Operative 3 Specimen Handling 3 Sodium Chloride 3 Radiosurgery 3 Opdualag 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Melanoma × Tranexamic Acid × Clear all

NCT05899465 2025-03-18

PRIME

University of Aarhus

Phase 3 Recruiting

Melanoma, Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡